Clene Nanomedicine Presents Updated Blinded Efficacy Data from Ongoing Phase 2 RESCUE-ALS Study at the ENCALS 2021 Annual MeetingGlobeNewsWire • 05/12/21
Clene Nanomedicine Receives Two Patent Notice of Allowances in the U.S. for Its Platform Nanocrystal Therapeutic TechnologyGlobeNewsWire • 04/30/21
Clene Nanomedicine Announces Upcoming Presentations at the Maxim Group LLC Inaugural 2021 Emerging Growth Virtual Conference and Launch of Clene Spotlight Webpage on M Vest LLCGlobeNewsWire • 03/10/21
Clene Nanomedicine Announces Achievement of 50% Enrollment in the Phase 3 HEALEY ALS Platform TrialGlobeNewsWire • 03/09/21
Clene's Lead Candidate Shows Improvement In Functional Scores In Multiple Sclerosis StudiesBenzinga • 02/25/21
Clene Nanomedicine Presents Updated Interim Data from Phase 2 Multiple Sclerosis Programs at ACTRIMS Forum 2021GlobeNewsWire • 02/25/21
Clene Nanomedicine to Present Updated Interim Data from Phase 2 Multiple Sclerosis Programs at ACTRIMS Forum 2021GlobeNewsWire • 02/19/21
Clene Nanomedicine Initiates Phase 2 Study of CNM-ZnAg for Patients with COVID-19GlobeNewsWire • 02/16/21
Clene Nanomedicine Closes Merger with Tottenham Acquisition I Limited and Provides Corporate UpdateGlobeNewsWire • 12/30/20